
zzso zzso targeting zzso the zzso for zzso have demonstrated zzso activity in zzso zzso zzso we further explore the therapeutic potential of the humanized zzso zzso zzso zzso as a single agent and in combination with standard of care cancer zzso zzso studies of zzso in zzso mice revealed a zzso of approximately three days suggesting twice a week dosing would be necessary to maintain zzso However, in multiple zzso models, zzso treatment resulted in extended tumor growth zzso up to zzso d following zzso of zzso suggesting that frequent administration of zzso may not be necessary to maintain prolonged zzso zzso zzso zzso studies revealed that zzso efficacy was achieved with zzso dosing once every two weeks, by either zzso or subcutaneous zzso zzso tumors that were initially treated with zzso and then zzso up to 1000 zzso following zzso of the first cycle of treatment remained sensitive to a second cycle of zzso zzso was also evaluated in patient derived primary colon tumor models, where efficacy compared favorably with a standard of care zzso Lastly, zzso enhanced the efficacy of several standard of care zzso including zzso in zzso breast tumor zzso zzso or zzso in zzso zzso cell lung zzso and zzso in zzso gastric zzso with no overlapping zzso These studies thus establish zzso as a promising therapeutic agent with durable zzso activity in human zzso as well as patient derived primary tumor models, and enhanced activity and zzso in combination with standard of care zzso Taken together, the data presented zzso suggest that zzso warrants evaluation in the zzso 

